Immunologic Effect and Tolerability of Intra-Seasonal Subcutaneous Immunotherapy With an 8-Day Up-Dosing Schedule to 10,000 Standardized Quality-Units: A Double-Blind, Randomized, Placebo-Controlled Trial
International guidelines recommend that allergen-specific immunotherapy for pollen-induced rhinoconjunctivitis is initiated preseasonally. However, because subjects often present to physicians with allergy symptoms during the pollen season, “within-season” initiation of specific immunotherapy is of...
Saved in:
| Published in | Clinical therapeutics Vol. 34; no. 10; pp. 2072 - 2081 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Bridgewater, NJ
Elsevier Inc
01.10.2012
Elsevier Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0149-2918 1879-114X 1879-114X |
| DOI | 10.1016/j.clinthera.2012.09.006 |
Cover
| Abstract | International guidelines recommend that allergen-specific immunotherapy for pollen-induced rhinoconjunctivitis is initiated preseasonally. However, because subjects often present to physicians with allergy symptoms during the pollen season, “within-season” initiation of specific immunotherapy is of special interest.
We evaluated the immunomodulatory effects and tolerability of subcutaneous immunotherapy (SCIT) with Standardized Quality (SQ) 6-grass mix and rye allergen extract, using an 8-day intra-seasonal up-dosing schedule to 10,000 SQ-units (SQ-U).
In a 9-week, multicenter, randomized, double-blind, placebo-controlled trial, adults (mean age, 34.6 years; 99.3% whites) with grass pollen–induced rhinoconjunctivitis (mean disease duration, 15.1 years) were randomized 3:1 to receive SCIT or placebo. Treatment was initiated during the 2008 pollen season, with an 8-day up-dosing from 100 to 10,000 SQ-U (6 daily injections) followed by 2 maintenance injections of 10,000 SQ-U at intervals of 2 and 4 weeks, respectively. The primary end point examined immunologic effects, assessing the difference in IgE-blocking factor (serum components competing with IgE for allergen binding) between SCIT and placebo at week 9. Secondary/explorative end points included the difference in IgE-blocking factor, specific IgG4, and specific IgE at various times. Tolerability (adverse events, local and systemic allergic reactions) of the up-dosing schedule was also evaluated.
Of the 148 treated subjects 144 (SCIT n = 109; placebo n = 35) were analyzed for the primary parameter. Immunologic response (significantly higher increase in IgE-blocking factor and IgG4 levels) occurred with SCIT versus placebo at week 9 (IgE-blocking factor, P = 0.0017; IgG4,P = 0.0215). Significant differences were observed as early as week 3. AEs were reported in 60.7% of SCIT- and 30.6% of placebo-treated subjects, with no treatment-related serious AEs. Local allergic reactions occurred in 46.4% of SCIT and 8.3% of placebo subjects (χ2 test, P < 0.0001). No significant difference was observed between groups in the incidence of systemic reactions (7.1% SCIT vs 5.6% placebo; χ2 test, P = 0.7413).
This trial provides the first description of short (8-day) intra-seasonal up-dosing with SCIT, which induced immunologic effects after only 3 weeks, and was generally well tolerated, although it induced a marked increase in the rate of local reactions compared with placebo. ClinicalTrials.gov identifier NCT00807547; ALK trial ID SHX0562. |
|---|---|
| AbstractList | International guidelines recommend that allergen-specific immunotherapy for pollen-induced rhinoconjunctivitis is initiated preseasonally. However, because subjects often present to physicians with allergy symptoms during the pollen season, "within-season" initiation of specific immunotherapy is of special interest. We evaluated the immunomodulatory effects and tolerability of subcutaneous immunotherapy (SCIT) with Standardized Quality (SQ) 6-grass mix and rye allergen extract, using an 8-day intra-seasonal up-dosing schedule to 10,000 SQ-units (SQ-U). In a 9-week, multicenter, randomized, double-blind, placebo-controlled trial, adults (mean age, 34.6 years; 99.3% whites) with grass pollen-induced rhinoconjunctivitis (mean disease duration, 15.1 years) were randomized 3:1 to receive SCIT or placebo. Treatment was initiated during the 2008 pollen season, with an 8-day up-dosing from 100 to 10,000 SQ-U (6 daily injections) followed by 2 maintenance injections of 10,000 SQ-U at intervals of 2 and 4 weeks, respectively. The primary end point examined immunologic effects, assessing the difference in IgE-blocking factor (serum components competing with IgE for allergen binding) between SCIT and placebo at week 9. Secondary/explorative end points included the difference in IgE-blocking factor, specific IgG4, and specific IgE at various times. Tolerability (adverse events, local and systemic allergic reactions) of the up-dosing schedule was also evaluated. Of the 148 treated subjects 144 (SCIT n = 109; placebo n = 35) were analyzed for the primary parameter. Immunologic response (significantly higher increase in IgE-blocking factor and IgG4 levels) occurred with SCIT versus placebo at week 9 (IgE-blocking factor, P = 0.0017; IgG4, P = 0.0215). Significant differences were observed as early as week 3. AEs were reported in 60.7% of SCIT- and 30.6% of placebo-treated subjects, with no treatment-related serious AEs. Local allergic reactions occurred in 46.4% of SCIT and 8.3% of placebo subjects (χ2 test, P < 0.0001). No significant difference was observed between groups in the incidence of systemic reactions (7.1% SCIT vs 5.6% placebo; χ2 test, P = 0.7413). This trial provides the first description of short (8-day) intra-seasonal up-dosing with SCIT, which induced immunologic effects after only 3 weeks, and was generally well tolerated, although it induced a marked increase in the rate of local reactions compared with placebo. ClinicalTrials.gov identifier NCT00807547; ALK trial ID SHX0562. International guidelines recommend that allergen-specific immunotherapy for pollen-induced rhinoconjunctivitis is initiated preseasonally. However, because subjects often present to physicians with allergy symptoms during the pollen season, “within-season” initiation of specific immunotherapy is of special interest. We evaluated the immunomodulatory effects and tolerability of subcutaneous immunotherapy (SCIT) with Standardized Quality (SQ) 6-grass mix and rye allergen extract, using an 8-day intra-seasonal up-dosing schedule to 10,000 SQ-units (SQ-U). In a 9-week, multicenter, randomized, double-blind, placebo-controlled trial, adults (mean age, 34.6 years; 99.3% whites) with grass pollen–induced rhinoconjunctivitis (mean disease duration, 15.1 years) were randomized 3:1 to receive SCIT or placebo. Treatment was initiated during the 2008 pollen season, with an 8-day up-dosing from 100 to 10,000 SQ-U (6 daily injections) followed by 2 maintenance injections of 10,000 SQ-U at intervals of 2 and 4 weeks, respectively. The primary end point examined immunologic effects, assessing the difference in IgE-blocking factor (serum components competing with IgE for allergen binding) between SCIT and placebo at week 9. Secondary/explorative end points included the difference in IgE-blocking factor, specific IgG4, and specific IgE at various times. Tolerability (adverse events, local and systemic allergic reactions) of the up-dosing schedule was also evaluated. Of the 148 treated subjects 144 (SCIT n = 109; placebo n = 35) were analyzed for the primary parameter. Immunologic response (significantly higher increase in IgE-blocking factor and IgG4 levels) occurred with SCIT versus placebo at week 9 (IgE-blocking factor, P = 0.0017; IgG4,P = 0.0215). Significant differences were observed as early as week 3. AEs were reported in 60.7% of SCIT- and 30.6% of placebo-treated subjects, with no treatment-related serious AEs. Local allergic reactions occurred in 46.4% of SCIT and 8.3% of placebo subjects (χ2 test, P < 0.0001). No significant difference was observed between groups in the incidence of systemic reactions (7.1% SCIT vs 5.6% placebo; χ2 test, P = 0.7413). This trial provides the first description of short (8-day) intra-seasonal up-dosing with SCIT, which induced immunologic effects after only 3 weeks, and was generally well tolerated, although it induced a marked increase in the rate of local reactions compared with placebo. ClinicalTrials.gov identifier NCT00807547; ALK trial ID SHX0562. Abstract Background International guidelines recommend that allergen-specific immunotherapy for pollen-induced rhinoconjunctivitis is initiated preseasonally. However, because subjects often present to physicians with allergy symptoms during the pollen season, “within-season” initiation of specific immunotherapy is of special interest. Objective We evaluated the immunomodulatory effects and tolerability of subcutaneous immunotherapy (SCIT) with Standardized Quality (SQ) 6-grass mix and rye allergen extract, using an 8-day intra-seasonal up-dosing schedule to 10,000 SQ-units (SQ-U). Methods In a 9-week, multicenter, randomized, double-blind, placebo-controlled trial, adults (mean age, 34.6 years; 99.3% whites) with grass pollen–induced rhinoconjunctivitis (mean disease duration, 15.1 years) were randomized 3:1 to receive SCIT or placebo. Treatment was initiated during the 2008 pollen season, with an 8-day up-dosing from 100 to 10,000 SQ-U (6 daily injections) followed by 2 maintenance injections of 10,000 SQ-U at intervals of 2 and 4 weeks, respectively. The primary end point examined immunologic effects, assessing the difference in IgE-blocking factor (serum components competing with IgE for allergen binding) between SCIT and placebo at week 9. Secondary/explorative end points included the difference in IgE-blocking factor, specific IgG4 , and specific IgE at various times. Tolerability (adverse events, local and systemic allergic reactions) of the up-dosing schedule was also evaluated. Results Of the 148 treated subjects 144 (SCIT n = 109; placebo n = 35) were analyzed for the primary parameter. Immunologic response (significantly higher increase in IgE-blocking factor and IgG4 levels) occurred with SCIT versus placebo at week 9 (IgE-blocking factor, P = 0.0017; IgG4, P = 0.0215). Significant differences were observed as early as week 3. AEs were reported in 60.7% of SCIT- and 30.6% of placebo-treated subjects, with no treatment-related serious AEs. Local allergic reactions occurred in 46.4% of SCIT and 8.3% of placebo subjects (χ2 test, P < 0.0001). No significant difference was observed between groups in the incidence of systemic reactions (7.1% SCIT vs 5.6% placebo; χ2 test, P = 0.7413). Conclusions This trial provides the first description of short (8-day) intra-seasonal up-dosing with SCIT, which induced immunologic effects after only 3 weeks, and was generally well tolerated, although it induced a marked increase in the rate of local reactions compared with placebo. ClinicalTrials.gov identifier NCT00807547 ; ALK trial ID SHX0562. International guidelines recommend that allergen-specific immunotherapy for pollen-induced rhinoconjunctivitis is initiated preseasonally. However, because subjects often present to physicians with allergy symptoms during the pollen season, "within-season" initiation of specific immunotherapy is of special interest.BACKGROUNDInternational guidelines recommend that allergen-specific immunotherapy for pollen-induced rhinoconjunctivitis is initiated preseasonally. However, because subjects often present to physicians with allergy symptoms during the pollen season, "within-season" initiation of specific immunotherapy is of special interest.We evaluated the immunomodulatory effects and tolerability of subcutaneous immunotherapy (SCIT) with Standardized Quality (SQ) 6-grass mix and rye allergen extract, using an 8-day intra-seasonal up-dosing schedule to 10,000 SQ-units (SQ-U).OBJECTIVEWe evaluated the immunomodulatory effects and tolerability of subcutaneous immunotherapy (SCIT) with Standardized Quality (SQ) 6-grass mix and rye allergen extract, using an 8-day intra-seasonal up-dosing schedule to 10,000 SQ-units (SQ-U).In a 9-week, multicenter, randomized, double-blind, placebo-controlled trial, adults (mean age, 34.6 years; 99.3% whites) with grass pollen-induced rhinoconjunctivitis (mean disease duration, 15.1 years) were randomized 3:1 to receive SCIT or placebo. Treatment was initiated during the 2008 pollen season, with an 8-day up-dosing from 100 to 10,000 SQ-U (6 daily injections) followed by 2 maintenance injections of 10,000 SQ-U at intervals of 2 and 4 weeks, respectively. The primary end point examined immunologic effects, assessing the difference in IgE-blocking factor (serum components competing with IgE for allergen binding) between SCIT and placebo at week 9. Secondary/explorative end points included the difference in IgE-blocking factor, specific IgG(4), and specific IgE at various times. Tolerability (adverse events, local and systemic allergic reactions) of the up-dosing schedule was also evaluated.METHODSIn a 9-week, multicenter, randomized, double-blind, placebo-controlled trial, adults (mean age, 34.6 years; 99.3% whites) with grass pollen-induced rhinoconjunctivitis (mean disease duration, 15.1 years) were randomized 3:1 to receive SCIT or placebo. Treatment was initiated during the 2008 pollen season, with an 8-day up-dosing from 100 to 10,000 SQ-U (6 daily injections) followed by 2 maintenance injections of 10,000 SQ-U at intervals of 2 and 4 weeks, respectively. The primary end point examined immunologic effects, assessing the difference in IgE-blocking factor (serum components competing with IgE for allergen binding) between SCIT and placebo at week 9. Secondary/explorative end points included the difference in IgE-blocking factor, specific IgG(4), and specific IgE at various times. Tolerability (adverse events, local and systemic allergic reactions) of the up-dosing schedule was also evaluated.Of the 148 treated subjects 144 (SCIT n = 109; placebo n = 35) were analyzed for the primary parameter. Immunologic response (significantly higher increase in IgE-blocking factor and IgG(4) levels) occurred with SCIT versus placebo at week 9 (IgE-blocking factor, P = 0.0017; IgG(4,)P = 0.0215). Significant differences were observed as early as week 3. AEs were reported in 60.7% of SCIT- and 30.6% of placebo-treated subjects, with no treatment-related serious AEs. Local allergic reactions occurred in 46.4% of SCIT and 8.3% of placebo subjects (χ(2) test, P < 0.0001). No significant difference was observed between groups in the incidence of systemic reactions (7.1% SCIT vs 5.6% placebo; χ(2) test, P = 0.7413).RESULTSOf the 148 treated subjects 144 (SCIT n = 109; placebo n = 35) were analyzed for the primary parameter. Immunologic response (significantly higher increase in IgE-blocking factor and IgG(4) levels) occurred with SCIT versus placebo at week 9 (IgE-blocking factor, P = 0.0017; IgG(4,)P = 0.0215). Significant differences were observed as early as week 3. AEs were reported in 60.7% of SCIT- and 30.6% of placebo-treated subjects, with no treatment-related serious AEs. Local allergic reactions occurred in 46.4% of SCIT and 8.3% of placebo subjects (χ(2) test, P < 0.0001). No significant difference was observed between groups in the incidence of systemic reactions (7.1% SCIT vs 5.6% placebo; χ(2) test, P = 0.7413).This trial provides the first description of short (8-day) intra-seasonal up-dosing with SCIT, which induced immunologic effects after only 3 weeks, and was generally well tolerated, although it induced a marked increase in the rate of local reactions compared with placebo. ClinicalTrials.gov identifier NCT00807547; ALK trial ID SHX0562.CONCLUSIONSThis trial provides the first description of short (8-day) intra-seasonal up-dosing with SCIT, which induced immunologic effects after only 3 weeks, and was generally well tolerated, although it induced a marked increase in the rate of local reactions compared with placebo. ClinicalTrials.gov identifier NCT00807547; ALK trial ID SHX0562. International guidelines recommend that allergen-specific immunotherapy for pollen-induced rhinoconjunctivitis is initiated preseasonally. However, because subjects often present to physicians with allergy symptoms during the pollen season, "within-season" initiation of specific immunotherapy is of special interest. We evaluated the immunomodulatory effects and tolerability of subcutaneous immunotherapy (SCIT) with Standardized Quality (SQ) 6-grass mix and rye allergen extract, using an 8-day intra-seasonal up-dosing schedule to 10,000 SQ-units (SQ-U). In a 9-week, multicenter, randomized, double-blind, placebo-controlled trial, adults (mean age, 34.6 years; 99.3% whites) with grass pollen-induced rhinoconjunctivitis (mean disease duration, 15.1 years) were randomized 3:1 to receive SCIT or placebo. Treatment was initiated during the 2008 pollen season, with an 8-day up-dosing from 100 to 10,000 SQ-U (6 daily injections) followed by 2 maintenance injections of 10,000 SQ-U at intervals of 2 and 4 weeks, respectively. The primary end point examined immunologic effects, assessing the difference in IgE-blocking factor (serum components competing with IgE for allergen binding) between SCIT and placebo at week 9. Secondary/explorative end points included the difference in IgE-blocking factor, specific IgG(4), and specific IgE at various times. Tolerability (adverse events, local and systemic allergic reactions) of the up-dosing schedule was also evaluated. Of the 148 treated subjects 144 (SCIT n = 109; placebo n = 35) were analyzed for the primary parameter. Immunologic response (significantly higher increase in IgE-blocking factor and IgG(4) levels) occurred with SCIT versus placebo at week 9 (IgE-blocking factor, P = 0.0017; IgG(4,)P = 0.0215). Significant differences were observed as early as week 3. AEs were reported in 60.7% of SCIT- and 30.6% of placebo-treated subjects, with no treatment-related serious AEs. Local allergic reactions occurred in 46.4% of SCIT and 8.3% of placebo subjects (χ(2) test, P < 0.0001). No significant difference was observed between groups in the incidence of systemic reactions (7.1% SCIT vs 5.6% placebo; χ(2) test, P = 0.7413). This trial provides the first description of short (8-day) intra-seasonal up-dosing with SCIT, which induced immunologic effects after only 3 weeks, and was generally well tolerated, although it induced a marked increase in the rate of local reactions compared with placebo. ClinicalTrials.gov identifier NCT00807547; ALK trial ID SHX0562. |
| Author | Wüstenberg, Eike Pfaar, Oliver Klimek, Ludger Schnitker, Jörg Wolf, Hendrik |
| Author_xml | – sequence: 1 givenname: Oliver surname: Pfaar fullname: Pfaar, Oliver email: oliver.pfaar@allergiezentrum.org organization: Center for Rhinology and Allergology, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Mannheim, Wiesbaden, Germany – sequence: 2 givenname: Hendrik surname: Wolf fullname: Wolf, Hendrik organization: ALK Arzneimittel GmbH, Wedel, Germany – sequence: 3 givenname: Ludger surname: Klimek fullname: Klimek, Ludger organization: Center for Rhinology and Allergology, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Mannheim, Wiesbaden, Germany – sequence: 4 givenname: Jörg surname: Schnitker fullname: Schnitker, Jörg organization: Institut für angewandte Statistik GmbH, Bielefeld, Germany – sequence: 5 givenname: Eike surname: Wüstenberg fullname: Wüstenberg, Eike organization: ALK Arzneimittel GmbH, Wedel, Germany |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26555172$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23063373$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkt9u0zAYxSM0xLrBK4AlhMTFUvw5TlIjARrtgEmT-NNNcGc5zpfVxYmLnSCVZ-ShcOjYpElIu_LN7xwfH5-DZK9zHSbJE6BToFC8WE-1NV2_Qq-mjAKbUjGltLiXTGBWihSAf9tLJhS4SJmA2X5yEMKaUpqJnD1I9llGiywrs0ny-7Rth85Zd2k0OWka1D1RXU3OnY3elbGm3xLXkNOu9ypdogquU5Ysh0oPverQDYHsLP6G2WzJV9OvogWZpQu1JRebdOGC6S7JUq-wHiyS3hGgRzEMWUaHWvna_MKafB7UeFl60Zk-vCTHZOGGymL6Nj60PiJfIurakTwin6zSWLl07mIqZ21Un3uj7MPkfqNswEdX52Fy8e7kfP4hPfv4_nR-fJbqnNM-5YUQeVHVGc1rzngBtEYQpeJMx7LKIseMcgYcCs1FVswQMihL5IJVWgA02WHyfOe78e7HgKGXrQkard0VIgGAZTyjABF9egtdu8HHCiNFYwoxizdF6vEVNVQt1nLjTav8Vv77pwg8uwJU0Mo2XnXahBuuyPMcSha5csdp70Lw2FwjQOW4HLmW18uR43IkFTIuJypf3VJq06vejBUrY--gP97pMRb_06CXQRvsNNbGx1HJ2pk7eLy-5TFyJj74O24x3DQnQ9TI5bjvcd7AKM3ZjEaDN_83uFOEP3BVDgk |
| CitedBy_id | crossref_primary_10_1111_all_13392 crossref_primary_10_1111_all_13464 crossref_primary_10_1177_1945892421999649 crossref_primary_10_2217_imt_2019_0086 crossref_primary_10_1007_s00105_014_2817_0 crossref_primary_10_1111_all_13358 crossref_primary_10_1002_clt2_12373 crossref_primary_10_1007_s40629_014_0032_2 crossref_primary_10_1111_ddg_12782 crossref_primary_10_1111_cea_12241 crossref_primary_10_1159_000503684 crossref_primary_10_1007_s15007_014_0707_5 crossref_primary_10_1111_ddg_10_12782 crossref_primary_10_2217_imt_14_23 crossref_primary_10_34689_SH_2020_22_2_004 crossref_primary_10_1016_j_jaip_2016_05_014 |
| Cites_doi | 10.1111/j.1398-9995.2009.02194.x 10.1185/030079907X187865 10.1016/S0091-6749(97)70190-8 10.1111/j.1398-9995.2012.02801.x 10.1016/j.jaci.2005.11.014 10.1034/j.1398-9995.2000.00368.x 10.1111/j.1398-9995.2011.02736.x 10.4049/jimmunol.172.5.3252 10.1046/j.1365-2222.2003.01699.x 10.1111/j.1398-9995.2011.02745.x 10.1111/j.1398-9995.2006.01219_1.x 10.1016/j.jaci.2008.01.072 10.1016/S1081-1206(10)60003-8 10.1016/S0091-6749(99)70524-5 10.1097/ACI.0b013e328339505c 10.1016/j.clinthera.2011.06.006 10.1111/j.1398-9995.2007.01620.x 10.1111/j.1398-9995.2007.01455.x 10.1016/j.jaci.2008.10.044 10.1067/mai.2001.118891 10.1067/mai.2001.112027 |
| ContentType | Journal Article |
| Copyright | 2012 Elsevier HS Journals, Inc. Elsevier HS Journals, Inc. 2015 INIST-CNRS Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved. |
| Copyright_xml | – notice: 2012 Elsevier HS Journals, Inc. – notice: Elsevier HS Journals, Inc. – notice: 2015 INIST-CNRS – notice: Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved. |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88C 88E 8AO 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. KB0 M0S M0T M1P M2O M7N MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 |
| DOI | 10.1016/j.clinthera.2012.09.006 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Research Library Prep MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1879-114X |
| EndPage | 2081 |
| ExternalDocumentID | 2785770131 23063373 26555172 10_1016_j_clinthera_2012_09_006 S0149291812005280 1_s2_0_S0149291812005280 |
| Genre | Multicenter Study Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Denmark Germany |
| GeographicLocations_xml | – name: Denmark – name: Germany |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1~. 1~5 29B 4.4 457 4G. 53G 5RE 5VS 6J9 6PF 7-5 71M 7RV 7X7 88E 8AO 8FI 8FJ 8G5 8P~ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABUWG ABWVN ABXDB ABZDS ACDAQ ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI ASPBG AVWKF AXJTR AZFZN AZQEC BENPR BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EBS EFJIC EFKBS EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HMCUK HVGLF HZ~ H~9 IHE J1W KOM M0T M1P M2O M41 MO0 N9A NAPCQ O-L O9- OAUVE OD~ OGGZJ OO0 OZT P-8 P-9 PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO Q38 R2- ROL RPZ SCC SDF SDG SEL SES SEW SPCBC SSH SSP SSZ SV3 T5K UHS UKHRP WH7 WOW XOL Z5R ZGI ZXP ~G- 0SF 3V. AACTN AAYOK AFCTW AFKWA AJOXV ALIPV AMFUW NCXOZ RIG AAIAV AATCM ABLVK ABYKQ AJBFU EFLBG LCYCR AAYXX AGRNS CITATION IQODW CGR CUY CVF ECM EIF NPM 7XB 8FK K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c540t-469956bd305d424610de197a42c291765e30421416c49368e13177e492bc911f3 |
| IEDL.DBID | AIKHN |
| ISSN | 0149-2918 1879-114X |
| IngestDate | Thu Sep 04 22:18:46 EDT 2025 Sat Jul 26 03:07:13 EDT 2025 Mon Jul 21 05:57:12 EDT 2025 Mon Jul 21 09:14:54 EDT 2025 Tue Jul 01 04:21:29 EDT 2025 Thu Apr 24 23:08:12 EDT 2025 Fri Feb 23 02:23:21 EST 2024 Sun Feb 23 10:18:51 EST 2025 Tue Aug 26 16:34:09 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | intra-seasonal up-dosing 6-grass mix and rye subcutaneous immunotherapy (SCIT) allergic rhinoconjunctivitis safety Allergy Nose disease Rhinitis Toxicity Conjunctiva disease Conjunctivitis Posology Immunotherapy Quality ENT disease Clinical trial Subcutaneous administration Safety Rye Immunopathology Subcutaneous Randomized controlled trial Eye disease Treatment Mixed Placebo Double blind study |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c540t-469956bd305d424610de197a42c291765e30421416c49368e13177e492bc911f3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 content type line 14 ObjectType-Feature-3 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| PMID | 23063373 |
| PQID | 1095698421 |
| PQPubID | 1226358 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_1112343011 proquest_journals_1095698421 pubmed_primary_23063373 pascalfrancis_primary_26555172 crossref_primary_10_1016_j_clinthera_2012_09_006 crossref_citationtrail_10_1016_j_clinthera_2012_09_006 elsevier_sciencedirect_doi_10_1016_j_clinthera_2012_09_006 elsevier_clinicalkeyesjournals_1_s2_0_S0149291812005280 elsevier_clinicalkey_doi_10_1016_j_clinthera_2012_09_006 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-10-01 |
| PublicationDateYYYYMMDD | 2012-10-01 |
| PublicationDate_xml | – month: 10 year: 2012 text: 2012-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Bridgewater, NJ |
| PublicationPlace_xml | – name: Bridgewater, NJ – name: United States – name: Bridgewater |
| PublicationTitle | Clinical therapeutics |
| PublicationTitleAlternate | Clin Ther |
| PublicationYear | 2012 |
| Publisher | Elsevier Inc Elsevier Elsevier Limited |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier – name: Elsevier Limited |
| References | Ott, Sieber, Brehler (bib4) 2009; 64 Frew, Powell, Corrigan, Durham (bib8) 2006; 117 Bousquet, Van Cauwenberge, Khaltaev (bib2) 2001; 108 Justicia, Barasona, Serrano (bib17) 2007; 17 Shamji, Ljørring, Francis (bib23) 2012; 67 Zenner, Baumgarten, Rasp (bib24) 1997; 100 Pfaar, Urry, Robinson (bib22) 2012; 67 Powell, Frew, Corrigan, Durham (bib13) 2007; 62 Ohashi, Nakai, Tanaka (bib18) 1998; 538 Bousquet, Khaltaev, Cruz (bib1) 2008; 63 Winther, Malling, Mosbech (bib19) 2000; 55 Machin, Campbell, Fayers, Pinol (bib12) 1997 Reich, Gessner, Kroker (bib5) 2011; 33 Mothes, Heinzkill, Drachenberg (bib20) 2003; 33 Pfaar, Jung, Wolf (bib10) 2012; 67 Bufe, Eberle, Franke-Beckmann (bib9) 2009; 123 Cox (bib6) 2006; 97 Keiding, Jørgensen (bib14) 2007; 23 Alvarez-Cuesta, Bousquet, Canonica (bib3) 2006; 61 Walker, Pajno, Lima (bib16) 2001; 107 Francis, James, Paraskevopoulos (bib15) 2008; 121 Pfaar, Leitzbach, Hormann, Klimek (bib7) 2010; 10 Klimek, Wolf, Mewes (bib11) 1999; 103 Nouri-Aria, Wachholz, Francis (bib21) 2004; 172 Francis (10.1016/j.clinthera.2012.09.006_bib15) 2008; 121 Machin (10.1016/j.clinthera.2012.09.006_bib12) 1997 Cox (10.1016/j.clinthera.2012.09.006_bib6) 2006; 97 Shamji (10.1016/j.clinthera.2012.09.006_bib23) 2012; 67 Pfaar (10.1016/j.clinthera.2012.09.006_bib7) 2010; 10 Justicia (10.1016/j.clinthera.2012.09.006_bib17) 2007; 17 Bufe (10.1016/j.clinthera.2012.09.006_bib9) 2009; 123 Winther (10.1016/j.clinthera.2012.09.006_bib19) 2000; 55 Keiding (10.1016/j.clinthera.2012.09.006_bib14) 2007; 23 Pfaar (10.1016/j.clinthera.2012.09.006_bib10) 2012; 67 Mothes (10.1016/j.clinthera.2012.09.006_bib20) 2003; 33 Klimek (10.1016/j.clinthera.2012.09.006_bib11) 1999; 103 Powell (10.1016/j.clinthera.2012.09.006_bib13) 2007; 62 Walker (10.1016/j.clinthera.2012.09.006_bib16) 2001; 107 Reich (10.1016/j.clinthera.2012.09.006_bib5) 2011; 33 Ohashi (10.1016/j.clinthera.2012.09.006_bib18) 1998; 538 Pfaar (10.1016/j.clinthera.2012.09.006_bib22) 2012; 67 Alvarez-Cuesta (10.1016/j.clinthera.2012.09.006_bib3) 2006; 61 Zenner (10.1016/j.clinthera.2012.09.006_bib24) 1997; 100 Frew (10.1016/j.clinthera.2012.09.006_bib8) 2006; 117 Ott (10.1016/j.clinthera.2012.09.006_bib4) 2009; 64 Nouri-Aria (10.1016/j.clinthera.2012.09.006_bib21) 2004; 172 Bousquet (10.1016/j.clinthera.2012.09.006_bib1) 2008; 63 Bousquet (10.1016/j.clinthera.2012.09.006_bib2) 2001; 108 |
| References_xml | – volume: 121 start-page: 1120 year: 2008 end-page: 1125 ident: bib15 article-title: Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG publication-title: J Allergy Clin Immunol – volume: 172 start-page: 3252 year: 2004 end-page: 3259 ident: bib21 article-title: Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity publication-title: J Immunol – volume: 67 start-page: 272 year: 2012 end-page: 279 ident: bib22 article-title: A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy publication-title: Allergy – volume: 67 start-page: 217 year: 2012 end-page: 226 ident: bib23 article-title: Functional rather than immunoreactive levels of IgG publication-title: Allergy – volume: 17 start-page: 386 year: 2007 end-page: 392 ident: bib17 article-title: Predicting patients at high-risk of systemic reactions to cluster allergen immunotherapy: a pilot prospective observational study publication-title: J Investig Allergol Immunol – volume: 61 start-page: 1 year: 2006 end-page: 20 ident: bib3 article-title: Standards for practical allergen-specific immunotherapy publication-title: Allergy – volume: 62 start-page: 1335 year: 2007 end-page: 1338 ident: bib13 article-title: Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis publication-title: Allergy – volume: 538 start-page: 113 year: 1998 end-page: 117 ident: bib18 article-title: Risk factors for adverse systemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts publication-title: Acta Otolaryngol Suppl – volume: 100 start-page: 23 year: 1997 end-page: 29 ident: bib24 article-title: Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis publication-title: J Allergy Clin Immunol – volume: 10 start-page: 188 year: 2010 end-page: 193 ident: bib7 article-title: Cluster protocols in SCIT: enough evidence for practical use? publication-title: Curr Opin Allergy Clin Immunol – volume: 55 start-page: 827 year: 2000 end-page: 835 ident: bib19 article-title: Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis publication-title: Allergy – volume: 63 start-page: 8 year: 2008 end-page: 160 ident: bib1 article-title: Allergic Rhinitis and its Impact on Asthma (ARIA), 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) publication-title: Allergy – volume: 64 start-page: 1394 year: 2009 end-page: 1401 ident: bib4 article-title: Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study publication-title: Allergy – volume: 123 start-page: 167 year: 2009 end-page: 173 ident: bib9 article-title: Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy publication-title: J Allergy Clin Immunol – volume: 33 start-page: 1198 year: 2003 end-page: 1208 ident: bib20 article-title: Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies publication-title: Clin Exp Allergy – volume: 97 start-page: 126 year: 2006 end-page: 137 ident: bib6 article-title: Accelerated immunotherapy schedules: review of efficacy and safety publication-title: Ann Allergy Asthma Immunol – volume: 108 start-page: S147 year: 2001 end-page: S334 ident: bib2 article-title: Allergic rhinitis and its impact on asthma publication-title: J Allergy Clin Immunol – volume: 67 start-page: 630 year: 2012 end-page: 637 ident: bib10 article-title: Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimised allergen/adjuvant ratio publication-title: Allergy – year: 1997 ident: bib12 article-title: Sample Size Tables for Clinical Studies – volume: 33 start-page: 828 year: 2011 end-page: 840 ident: bib5 article-title: Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis publication-title: Clin Ther – volume: 117 start-page: 319 year: 2006 end-page: 325 ident: bib8 article-title: Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis publication-title: J Allergy Clin Immunol – volume: 103 start-page: 47 year: 1999 end-page: 53 ident: bib11 article-title: The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions publication-title: J Allergy Clin Immunol – volume: 23 start-page: 1113 year: 2007 end-page: 1120 ident: bib14 article-title: A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries publication-title: Curr Med Res Opin – volume: 107 start-page: 87 year: 2001 end-page: 93 ident: bib16 article-title: Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial publication-title: J Allergy Clin Immunol – volume: 64 start-page: 1394 year: 2009 ident: 10.1016/j.clinthera.2012.09.006_bib4 article-title: Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study publication-title: Allergy doi: 10.1111/j.1398-9995.2009.02194.x – volume: 23 start-page: 1113 year: 2007 ident: 10.1016/j.clinthera.2012.09.006_bib14 article-title: A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries publication-title: Curr Med Res Opin doi: 10.1185/030079907X187865 – volume: 100 start-page: 23 year: 1997 ident: 10.1016/j.clinthera.2012.09.006_bib24 article-title: Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis publication-title: J Allergy Clin Immunol doi: 10.1016/S0091-6749(97)70190-8 – volume: 67 start-page: 630 year: 2012 ident: 10.1016/j.clinthera.2012.09.006_bib10 article-title: Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimised allergen/adjuvant ratio publication-title: Allergy doi: 10.1111/j.1398-9995.2012.02801.x – volume: 117 start-page: 319 year: 2006 ident: 10.1016/j.clinthera.2012.09.006_bib8 article-title: Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2005.11.014 – volume: 55 start-page: 827 year: 2000 ident: 10.1016/j.clinthera.2012.09.006_bib19 article-title: Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis publication-title: Allergy doi: 10.1034/j.1398-9995.2000.00368.x – volume: 67 start-page: 272 year: 2012 ident: 10.1016/j.clinthera.2012.09.006_bib22 article-title: A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy publication-title: Allergy doi: 10.1111/j.1398-9995.2011.02736.x – volume: 172 start-page: 3252 year: 2004 ident: 10.1016/j.clinthera.2012.09.006_bib21 article-title: Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity publication-title: J Immunol doi: 10.4049/jimmunol.172.5.3252 – volume: 33 start-page: 1198 year: 2003 ident: 10.1016/j.clinthera.2012.09.006_bib20 article-title: Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies publication-title: Clin Exp Allergy doi: 10.1046/j.1365-2222.2003.01699.x – volume: 67 start-page: 217 year: 2012 ident: 10.1016/j.clinthera.2012.09.006_bib23 article-title: Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy publication-title: Allergy doi: 10.1111/j.1398-9995.2011.02745.x – volume: 61 start-page: 1 issue: Suppl 82 year: 2006 ident: 10.1016/j.clinthera.2012.09.006_bib3 article-title: Standards for practical allergen-specific immunotherapy publication-title: Allergy doi: 10.1111/j.1398-9995.2006.01219_1.x – volume: 121 start-page: 1120 year: 2008 ident: 10.1016/j.clinthera.2012.09.006_bib15 article-title: Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2008.01.072 – volume: 97 start-page: 126 year: 2006 ident: 10.1016/j.clinthera.2012.09.006_bib6 article-title: Accelerated immunotherapy schedules: review of efficacy and safety publication-title: Ann Allergy Asthma Immunol doi: 10.1016/S1081-1206(10)60003-8 – volume: 103 start-page: 47 year: 1999 ident: 10.1016/j.clinthera.2012.09.006_bib11 article-title: The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions publication-title: J Allergy Clin Immunol doi: 10.1016/S0091-6749(99)70524-5 – volume: 10 start-page: 188 year: 2010 ident: 10.1016/j.clinthera.2012.09.006_bib7 article-title: Cluster protocols in SCIT: enough evidence for practical use? publication-title: Curr Opin Allergy Clin Immunol doi: 10.1097/ACI.0b013e328339505c – volume: 33 start-page: 828 year: 2011 ident: 10.1016/j.clinthera.2012.09.006_bib5 publication-title: Clin Ther doi: 10.1016/j.clinthera.2011.06.006 – volume: 63 start-page: 8 issue: Suppl 86 year: 2008 ident: 10.1016/j.clinthera.2012.09.006_bib1 article-title: Allergic Rhinitis and its Impact on Asthma (ARIA), 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) publication-title: Allergy doi: 10.1111/j.1398-9995.2007.01620.x – volume: 62 start-page: 1335 year: 2007 ident: 10.1016/j.clinthera.2012.09.006_bib13 article-title: Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis publication-title: Allergy doi: 10.1111/j.1398-9995.2007.01455.x – volume: 123 start-page: 167 year: 2009 ident: 10.1016/j.clinthera.2012.09.006_bib9 article-title: Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2008.10.044 – volume: 538 start-page: 113 year: 1998 ident: 10.1016/j.clinthera.2012.09.006_bib18 article-title: Risk factors for adverse systemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts publication-title: Acta Otolaryngol Suppl – volume: 108 start-page: S147 issue: Suppl 5 year: 2001 ident: 10.1016/j.clinthera.2012.09.006_bib2 article-title: Allergic rhinitis and its impact on asthma publication-title: J Allergy Clin Immunol doi: 10.1067/mai.2001.118891 – volume: 17 start-page: 386 year: 2007 ident: 10.1016/j.clinthera.2012.09.006_bib17 article-title: Predicting patients at high-risk of systemic reactions to cluster allergen immunotherapy: a pilot prospective observational study publication-title: J Investig Allergol Immunol – volume: 107 start-page: 87 year: 2001 ident: 10.1016/j.clinthera.2012.09.006_bib16 article-title: Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial publication-title: J Allergy Clin Immunol doi: 10.1067/mai.2001.112027 – year: 1997 ident: 10.1016/j.clinthera.2012.09.006_bib12 article-title: Sample Size Tables for Clinical Studies |
| SSID | ssj0003952 |
| Score | 2.135312 |
| Snippet | International guidelines recommend that allergen-specific immunotherapy for pollen-induced rhinoconjunctivitis is initiated preseasonally. However, because... Abstract Background International guidelines recommend that allergen-specific immunotherapy for pollen-induced rhinoconjunctivitis is initiated preseasonally.... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2072 |
| SubjectTerms | 6-grass mix and rye Adolescent Adult Aged Allergens - administration & dosage Allergens - immunology allergic rhinoconjunctivitis Allergies Asthma Biological and medical sciences Clinical medicine Conjunctivitis, Allergic - immunology Conjunctivitis, Allergic - therapy Dose-Response Relationship, Immunologic Double-Blind Method Female Humans Immune system Immunoglobulin E - immunology Immunoglobulin G - immunology Immunotherapy - adverse effects Immunotherapy - methods Injections, Subcutaneous Internal Medicine intra-seasonal up-dosing Male Medical Education Medical sciences Middle Aged Non tumoral diseases Otorhinolaryngology. Stomatology Pharmacology. Drug treatments Plant Extracts - administration & dosage Plant Extracts - immunology Poaceae - immunology Pollen - immunology Practice Guidelines as Topic Quality of life Rhinitis, Allergic, Seasonal - immunology Rhinitis, Allergic, Seasonal - therapy safety Seasons Secale - immunology Statistical analysis subcutaneous immunotherapy (SCIT) Technical communication Time Factors Treatment Outcome Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology Young Adult |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdgSAgJIRhfhTEdEtpTLeXbyV7Q2Jg2pKGKtqJvVuw42lBoCmkfwt_IH8WdnaSaNBjP8TmJfT7_fL77HWPv4jL2U60NL4so4Ij_c650KbjQxs9FGmovpwTni8_J2Tz6tIgXncOt6cIqe5toDXVRa_KR4-pGJJ-lUeC_X_3gVDWKble7Ehp32T1LXYb6LBbDgcsLM1txh04BPMj89Fp8F2Ue2hwniu8KLNkplT26eXd6uMobHLPSFbv4Oxq1u9LpY_aog5Nw5Ob_Cbtjlrvs_kV3Yb7LDiaOmrodw2ybadWM4QAmW9Lq9in7fU6JIs4SgqM0hnxZwKyuUMxG0LZQl3BOzmA-NbmF8IB2R28QX5p604DrwmV0tfD1an2JXUDKT_IW5it-UpNfAqaoJsWmMrCuwffGOIAw7fwZV79MAY7Vo-WEhptDOALE-Koy_AOOZDGGL9i0_k4txzChOwBV82MXb1-h9IwW1DM2P_04Oz7jXaUHrhExrjme0XF2VYHGB1WGKOAL42cijwKN8yaS2JDXxUfwqKMsTFLjI-wRJsoCpdFal-FztrOsl-YlAz_J4yTUWhH3mkiVEmlReloJFQtTmGDEkn6Gpe5o0KkaRyX7eLdvclANSaohvUyiaoyYNwiuHBPI7SJpr0KyT3RF0yxxt7pdVNwkaprOxDTSlw02ttF5GSm3bzm0Um_EDgfJDkU5dPR_r92_punDnwZJjNha4PDt9aovt58yrM0Rezs8RjtFl09OBemkGYQRbScj9sItmW3neG4NQxG--nfnr9kD-lQXSrnHdtY_N-YNQsK12rfr_g8XCWD6 priority: 102 providerName: ProQuest |
| Title | Immunologic Effect and Tolerability of Intra-Seasonal Subcutaneous Immunotherapy With an 8-Day Up-Dosing Schedule to 10,000 Standardized Quality-Units: A Double-Blind, Randomized, Placebo-Controlled Trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0149291812005280 https://www.clinicalkey.es/playcontent/1-s2.0-S0149291812005280 https://dx.doi.org/10.1016/j.clinthera.2012.09.006 https://www.ncbi.nlm.nih.gov/pubmed/23063373 https://www.proquest.com/docview/1095698421 https://www.proquest.com/docview/1112343011 |
| Volume | 34 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Rb9MwELZGJyEkhGDAKIzqkNCeatYkTZzsres2taBV1dqKvlmJ44ii0lSkfQgP_EJ-FHdxkqpiaEi8tGrrc1z7_N1n--7M2Hs3cS1fKc2TuGtz5P8hj1QiuFDaCoXvqE5IAc43I28w636cu_MD1q9iYcitssR-g-kFWpffnJW9ebZeLM7ILQltO1ko2tv0cd1-aDuB5zbYYW_4aTCqAdkJiot3qDwngT03LwpALEKdyM3LLnKe0u1Hdxupx-sww65LzJ0XfyelhXG6fsqelKwSeqbhz9iBXh2xhzflufkROx2bDNV5G6a7gKusDacw3uWuzp-zX0OKFzGACCazMYSrGKbpEsUKR9oc0gSGtCfMJzosmDwg_Kgt0kydbjMwVZjArhw-LzZfsArw-WWYw2zNL1PanoAJaku8XWrYpGB12tiBMCm3NRY_dAwmuUfOiRRn59ADpPrRUvML7Mm4DbdYNP1GJdswpqOAKOV943a_ROkpzasXbHZ9Ne0PeHnhA1dIHDccl-q4XItixCDUHMoEH2srEGHXVjhuwnM1bb5YyCFVN3A8X1vIfoRGNYgUgnbivGSNVbrSrxhYXuh6jlIRpWATfhQJP046KhKRK3Ss7SbzqhGWqsyGTpdyLGXl9vZV1qohSTVkJ5CoGk3WqQXXJiHI_SJ-pUKyindFhJZotO4XFXeJ6qxEmkxaMsPC8o_Z0GTnteTehPq3x7b2NL3-p7bnIsUW2H0nlerLXVMoqWXg4wg12bv6Z4QrOoMyKkgLTtvpklVpsmMzZXaV4_LVcYTz-n-a_oY9ok_G3_KENTbft_ot8sZN1GIPPvy08FXMRavECHy_uBqNb38D9X5wtQ |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJwESQjBuhTEOEuyplnK_TEJoWze1bK2qtRV7M4njiKHSFNIKhR_FL-FHcU6cpJo0GC97rs-Ja38-F_tcGHvjpq4ZSKl4mjgWR_s_4rFMfe5LZUZ-YEsjogTnwdDrTZ0P5-75BvtV58JQWGUtE0tBnWSS7sjxdKMlHwaOZb5ffOPUNYpeV-sWGhoWJ6r4gS5b_q7fxf19a1nHR5PDHq-6CnCJ1smSoz-InOIEgY7To3LjiTJDP3IsaaHv4rmKPHwTDRXphLYXKBNVrK-c0IolSobURr632KZDGa0ttnlwNBydNbLfDsseP-R3cOQWXIooo1zHMquKIsqssrwqNVq6Wh_eW0Q57lKq22v83f4t9eDxA3a_MmBhXyPuIdtQ8y12e1A90W-x3ZEuhl10YLLO7co7sAujdZns4hH73afUFC17QRdRhmiewCSbIVkZs1tAlkKfrp_5WEWl0wAo6eQKLVqVrXLQLHQOWQEfL5afkQUEvBsVMF3wbkY3ITBGYCarmYJlBqbRwQWEcXWDcvFTJaDriBSc7O98D_YBvYp4pvgBrmTSgTMcmn2lkR0Y0atDnPFDHeE_Q-oJHeHHbHojKHjCWvNsrp4xML3I9WwpY6r25gdx7AdJasjYj11fJcpqM6_eYSGrwuvU_2Mm6gi7L6KBhiBoCCMUCI02MxrCha49cj1JUENI1Km1qAwE6sfrSf2rSFVeCbVcmCLHwWU8YEjgNsuqXYHRZnsNZWW3aXvs_z67cwnpzT-1PBeteR-Xb7uGvlhPpZEGbfa6-RklIz13aQiSb2vZDimwNnuqj8yaOXrKtu3bz__N_BW705sMTsVpf3jygt2laetAzm3WWn5fqZdokC7jnUoKAPt004LnDw0Jm1E |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELbGkCYkhGC8FcY4JNinWuTdySSExkq1MjZVtBX9ZhLHEUOlKaQVCj-N38CP4i5OUk0ajC_7XN_FTR6fn7PvhbHnfubboVKaZ6nncOT_MU9UJrhQ2o5F6CorpgTnk9PgaOK9m_rTDfaryYWhsMrGJlaGOs0VnZHj6kYmH4WeY7_M6rCIYa__evGNUwcpumlt2mkYiBzr8ge6b8WrQQ-_9QvH6b8dHx7xusMAV8hUlhx9Q9SapAh6nCqVHk-1HYnYc5SDfkzga_L2bSQtyovcINQ2brdCe5GTKLQSmYt6r7HrwkVWhWtJTFtnz3KjqtsPeSAcdYXnYsso67HKr6LYMqcqtEotly7eGW8u4gK_V2YabfydCVc7Yv82u1VTWTgw2LvDNvR8m22d1Jf122xvaMpil10Yr7O8ii7swXBdMLu8y34PKEnFWGEw5ZQhnqcwzmcoVkXvlpBnMKCDaD7SceU-ANo8tUJuq_NVAUaFySYr4ePZ8jOqgJD34hImC97L6UwERgjRdDXTsMzBtrr4AmFUn6Wc_dQpmIoiJScmXuzDAaB_kcw0f4NvMu3CBxyaf6WRXRjS_UOS80MT6z9D6TEt5ntsciUYuM825_lcP2RgB7EfuEolVPdNhEkiwjSzVCISX-hUOx0WNF9YqroEO3UCmckm1u6LbKEhCRrSiiRCo8OsVnBhqpBcLhI2EJJNki1uCxJ3ystFxUWiuqjNWyFtWeDgKjIwInDbVf2u0Oqw_VayZnCGmf3fY3fPIb39p07gI68X-Pp2GujL9VRau9Bhz9qf0UbSxZeBIHm5juvRVtZhD8ySWStHn9l1hfvo38qfsi00N_L94PT4MbtBszYRnTtsc_l9pZ8gM10mu5UJAPbpqm3OH3hWnhg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunologic+Effect+and+Tolerability+of+Intra-Seasonal+Subcutaneous+Immunotherapy+With+an+8-Day+Up-Dosing+Schedule+to+10%2C000+Standardized+Quality-Units%3A+A+Double-Blind%2C+Randomized%2C+Placebo-Controlled+Trial&rft.jtitle=Clinical+therapeutics&rft.au=Pfaar%2C+Oliver&rft.au=Wolf%2C+Hendrik&rft.au=Klimek%2C+Ludger&rft.au=Schnitker%2C+J%C3%B6rg&rft.date=2012-10-01&rft.issn=0149-2918&rft.volume=34&rft.issue=10&rft.spage=2072&rft.epage=2081&rft_id=info:doi/10.1016%2Fj.clinthera.2012.09.006&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_clinthera_2012_09_006 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01492918%2FS0149291811X00255%2Fcov150h.gif |